As shown in Figure 1B, FAM107A had a relatively lower expression in bladder cancer, brain and central nervous system (CNS) cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer, kidney cancer, lung cancer, melanoma, pancreatic cancer, prostate cancer, and sarcoma. Here, FAM107A is linked to prostate carcinoma.